-
-
-
-
-
-
-
TD Cowen Starts Day One Biopharmaceuticals (DAWN) at Buy
-
-
-
-
-
-
-
Day One Announces Three Year Follow-Up Data From OJEMDAâ„¢ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
-
-
-
-
-
-
-
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress
-
-
-
-
-
-
-
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
-
-
-
-
-
-
-
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
-
-
-
-
-
-
-
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
-
-
-
-
-
-
-
Day One Biopharmaceuticals (DAWN) Announces Two New Appointments to Board of Directors
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

